RET and adenocarcinoma: In 1–2% of those with NSCLC (most often in adenocarcinomas, never-smokers, and younger patients), rearrangements between RET and CCDC6 (coiled-coil domain containing-6), KIF5B (kinesin family 5B), NCOA4 (nuclear receptor coactivator 4), or other domains ultimately results in dysregulated signaling and RET overexpression.